New Promising Alternatives for Mitral Regurgitation

PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life.

Infarto agudo de miocardio y lesiones de múltiples niveles

This study soon to be published in J Am Coll Cardiol Intv is just a 30-day report on the new transcatheter mitral valve repair system PASCAL (Edwards Lifesciences, Irvine, California), but it is a promising tool that increases our arsenal to treat the mitral valve.

Eligible patients should have mitral valve regurgitation grade 3+ or 4+ and be symptomatic, despite optimal medical treatment. Major adverse events were adjudicated by an independent committee and echocardiographic images assessed by a central laboratory. Primary safety end points were major events at 30 days.

Between 2017 and 2018, 62 patients were enrolled, mean age 76.5, more than half (51.6%) were in functional class III-IV. Etiology was 56% functional, 36% degenerative and 8% mixed.


Read also: DES with Bioresorbable Polymer vs. Bare Metal Stents in Primary PCI.


At 30 days, major event rate was 6.5% with 1.6% all-cause mortality and no stroke. 98% reached ≤2+ regurgitation grade and 86% ≤1+ grade (p=0.0001). As regards symptoms, 85% reached functional class I or II (p=0.0001).

6-minute walk test improved 36 meters (p=0.0018) and quality of life questionnaires improved, the Kansas City Cardiomyopathy Questionnaire improved 17 points (p<0.0001) and the score EQ-5D 10 points (p=0.0004).

Conclusion

The transcatheter mitral valve repair system PASCAL showed feasibility and safety to treat patients with mitral valve regurgitation 3+ to 4+, regardless etiology.

Clinical improvement was significant, as was functional class, exercise capacity and quality of life.

Original Title: Transcatheter Valve Repair for Patients With Mitral Regurgitation 30-Day Results of the CLASP Study.

Reference: D. Scott Lim et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...